Biological Therapies – Discover Revenue Prospects Now, Benefiting Your Authority Do you want to assess how high biological drug sales can go? Visiongain’s new analysis gives you those revenue forecasts to 2025 at overall world market, therapeutic class and national level. For biologics you discover data, opportunities, R&D and sales potentials.
Our updated report gives you multilevel revenue predictions for biotechnological drugs from 2015, helping you stay ahead. You also investigate trends, results, technologies and expected products, benefiting your reputation for technological and commercial insight.
With our study you also assess the influence of biosimilars and other emerging treatments on that lucrative, expanding pharma industry and market.
Read on, then, to explore the biologics market from 2015, also seeing predicted revenue.
Forecasts and other analysis show you where the best sales opportunities exist Our new report shows revenue forecasting to 2025, business results, sales growth rates and market shares. There you explore quantitative and qualitative analyses, assessing sales potentials and R&D. You gain 57 tables and 33 charts, with original research and analysis.
That way you assess clinical, technological and commercial trends, results and potentials such as these issues: • Why will the biologics market achieve revenue growth from 2015 to 2025, and what sales are possible from existing drugs and R&D? • When will that industry achieve worldwide revenues over $300bn? • What treatment classes give the most promise for developers, producers and sellers? • Who are the best-placed companies in the biopharma industry? • Where are the most important and promising regions for selling those treatments? • How will biological drug producers serve regulators, doctors, patients and payers?
Opportunities in biologics to benefit drug developers, producers and marketers In 2014 seven of the top ten best-selling drugs were biologics. Many opportunities remain for products based on proteins and related biopharma technologies. Our study lets you discover what segments are most likely to prosper, from 2015 to 2025, through forecasted sales.
Why struggle to find data and other information, losing time and missing out? Instead help your research, analyses, plans, proposals and presentations now. With Visiongain’s new investigation see how you can save time and benefit your reputation for commercial insight.
Although no single study covers everything, the following sections show how our new investigation benefits your work.
Predictions for that world market and submarkets – see what sales growth is possible Along with revenue prediction for the overall world market for biologics, our study shows forecasts from 2015 to 2025 for 13 individual submarkets: • Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents • Monoclonal antibodies (mAbs) • Fusion proteins • Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy • Vaccines.
Our report gives sales potentials of those biopharmaceuticals. See there how you can benefit your plans, decisions, presentations and proposals, also helping your influence.
That new investigation also discusses what stimulates and restrains sales of biologics. You explore that industry, seeing what products can achieve the most success. Discover, from 2015, how pharmaceutical companies can gain from biologics.
Our study also divides its overall world forecast into geographical segments.
National markets for therapeutic proteins – where will highest sales and growth occur? Our study predicts rising demand for biological drugs in developed and developing countries. Discover what sales results and expansion are possible from 2015.
The analyses show you individual revenue forecasts to 2025 for 11 national markets: • United States (US) • Japan • Germany, France, United Kingdom (UK), Italy and Spain (EU5 group) • Brazil, Russia, India and China (BRIC countries).
In our study you discover outlooks for improving treatment coverage and expanding revenues. You assess the biologic industry’s future – needs, developments, demands and opportunities.
Our work explores issues affecting biopharma companies, influencing their results.
Forces affecting the biological drugs industry – what shapes its present and future? The new report discusses pressures, opportunities and other events affecting the biologics industry and market from 2015, including these influences: • Achievements of leading drugs, including Rituxan, Humira, Remicade, Simponi, Stelara, Tysabri, Lantus, Avastin, Lucentis, Herceptin and Erbitux • Research and development, esp. potentials of recombinant DNA technology and emerging processes to benefit patients • Needs and opportunities for developing biologics, including rising prevalence of cancers, autoimmune and neurodegenerative disorders • Data exclusivity and patent challenges for biopharmaceuticals • New products, including Tresiba, Toujeo and Abasaglar • Next-generation biologics and biobetters – explore competition, technological races and battles, including progress in drug delivery systems.
Our study also discusses other aspects of biologics, including these forces: • Anti-cancer agents, erythropoietins, protease polymerase inhibitors, G-CSF and human growth hormones – investigate prospects for therapeutic classes • Treatments for haemophilia, diabetes, anaemia, bleeding disorders, wet AMD, multiple sclerosis, arthritis and other chronic diseases – assess developments • Pricing, reimbursement, clinical efficacy and other challenges – explore regulators’ and other healthcare payers’ demands for biologics, including biosimilars • Interchangeable biological products versus biosimilars – find how the FDA differs from the EMA • Collaborations, partnerships and networks shaping biopharma.
With our new analysis you assess that industry’s strengths, weaknesses, opportunities and threats. See what is happening. That way you explore what restricts and stimulates companies developing, manufacturing, marketing and selling biological medicines.
Companies and 2019 market value – what overall revenue potential? From 2015, biological product launches hold great potential for investments, demand and sales. Our study predicts the world market for those drugs will reach $270bn in 2019, with strong revenue expansion from 2015 to 2025. See how high revenues can go.
With our study you assess what biotechnologies, products and companies hold most potential. Our analyses cover these organisations: • AbbVie • Roche • Amgen • Johnson & Johnson • Novo Nordisk • Bristol-Myers Squibb • Pfizer • Merck & Co.
Our study also discusses these companies, among others: • Novartis • Sanofi • GSK • Eli Lilly • AstraZeneca • Teva Pharmaceutical Industries • Bayer • Biogen.
From 2015 there will arise many opportunities. Our work shows you commercial possibilities for biological drugs, helping you stay ahead in knowledge and succeed.
Ways Global Biologics Market, Industry and R&D: Forecasts 2015-2025 helps In these five main ways, our new study benefits your research, analyses, decisions, proposals and presentations: • Revenues to 2025 for biologics at overall world level – discover outlooks for development, production, marketing and sales • 13 submarkets’ revenues to 2025 – investigate that industry’s segments at world level, finding the most lucrative and fast-rising product groups • Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia – assess developed and developing countries for potential revenues • Prospects for established competitors and rising companies – explore product portfolios, results, strategies, R&D and outlooks for success • Analysis of what encourages and restrains biologic producers – investigate challenges, strengths and competition, helping you stay ahead and succeed.
That survey, by our in-house UK-based analysts, gives knowledge to benefit your work. Our study shows information you find nowhere else.
Independent analysis to benefit your authority on pharma biotechnology Our report provides independent analysis. It gives competitive intelligence found only in our study, helping you assess commercial prospects.
With that investigation you are less likely to fall behind in information or miss opportunity. Discover there how to benefit your searches, analyses, plans and decisions, also saving time and helping your influence. You assess, from 2015, potentials of biologics.
So explore the future of biopharmaceuticals. In our new study you find biologic data, trends, opportunities and sales predictions. Stay ahead by getting that report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Biologics Overview
1.2 Why you Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to the Biologics Market and Key Concepts
2.1 Biologics: Large and Complex Products
2.2 A Brief History of Biological Drug Development
2.3 Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?
2.4 What are Biosimilars?
2.4.1 Brief History of Biosimilars
2.4.2 What are Interchangeable Biological Products and how do they Differ from Biosimilars?
2.4.3 Prescription of Interchangeables vs Biosimilars and how this sets the FDA apart from the EMA
2.4.4 What Share of the Overall Biologics Market do they Currently Hold?
2.5 What are Next-Generation Biologics / Biobetters? What Share of the Overall Biologics Market do they Currently Hold?
2.6 Marginal Cases
2.7 Vaccines Market
3. The Global Biologics Market, 2015-2025
3.1 Global Biologics Market Forecast, 2015-2025
3.2 What Factors Will Drive Growth in the Biologics Market?
3.3 Ageing Population and the Rise of Chronic Disease
3.4 Seven of the Top Ten Best-Selling Drugs are Biologics
3.5 Biologics Constitute 19% of the Global Pharmaceutical Market - Further Launches will Drive Market
3.6 Biosimilars - Both an Opportunity and a Threat
3.7 What Factors will Restrain Growth in the Biologics Market?
3.8 High Costs in the Face of Declining National Healthcare Budgets
3.9 In Some Areas, Clinical Efficacy is not Superior Enough to Justify the Price Gap
3.10 Over $67bn worth of Biologic Patents due to Expire by 2020
3.11 Administration is often not as Convenient as that for Conventional Drugs
Table 4.17 Enzyme Replacement and Other Protein Therapeutics Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 4.18 Enzyme Replacement and Other Protein Therapeutics Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 5.1 Regions of an Antibody
Table 5.2 Natural Antibody Mechanisms of Action
Table 5.3 Top Five Best-Selling mAbs, 2014
Table 5.4 Selected Leading Autoimmune mAbs: Revenue ($bn), 2014
Table 5.5 Breakdown of Erbitux Revenues between Merck KGaA, Bristol-Myers Squibb and Eli Lilly: Revenue ($bn), Percentage Change (%), Percentage of 2014 Revenues (%), 2013 and 2014
Table 6.1 Amgen’s US Patents and Expiry Dates for Enbrel
Table 6.2 Breakdown of Eylea’s Revenues between Regeneron and Bayer, 2014 and 2013: Revenue ($bn), Percentage Change (%), Percentage of Profits (%), 2014
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.
From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
